Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

User Fees: Should US FDA Incur Penalties For Missed Deadlines?

Executive Summary

Sen. Burr asks FDA whether fee revenue should be rebated for not meeting some PDUFA V goals.

You may also be interested in...



US FDA Still Waiting For Cures Money, Woodcock Says

When asked about Cures-related hiring, CDER Director says to her knowledge, no funding has been received yet.

US FDA Might Face Funding Penalty For Missing User-Fee Goals

Industry representatives support adding a provision to the user-fee agreements that would withdraw some taxpayer funding if the agency does not meet its deliverables.

US FDA Might Face Funding Penalty For Missing User Fee Goals

Industry representatives support adding a provision to the user fee agreements that would withdraw some taxpayer funding if the agency does not meet its deliverables.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS120306

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel